The AZ Vaccine – Clot risks and questions about herd immunity – Lecture

   Rated 0 / 5 stars

Save

CPD for this activity

Educational Activities (EA)

0 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0 mins

Educational Activities (EA)
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0 mins

Reviewing Performance (RP)
These are activities that require reflection on feedback about your work.

MO
0 mins

Measuring Outcomes (MO)
These are activities that use your work data to ensure quality results.

Listen to the episode

Description

Dr Michelle Ananda-Rajah, will walk us through the data, help us understand our role as GPs and look at what can be done to get our patients and the country back on track to long term protection against COVID19. The AZ vaccine is a key part of the Australian COVID prevention strategy. However, we must ask ourselves whether or not the risk of adverse effects, especially clots, is acceptable in the Australian context where COVID is more or less under control. This is a vital issue to grasp if we are to make reliable recommendations to our patients. Furthermore, we must take a close look at whether or not the efficacy of the AZ vaccine is high enough for us to achieve herd immunity. As the public becomes increasingly hesitant with regard to the AZ vaccine, the likelihood of us vaccinating enough of the population to achieve herd immunity diminishes rapidly.

Last Updated: 26 May, 2021

Rate this podcast
Help your colleagues find podcasts they'll enjoy by rating this podcast out of five stars.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rod Baber

Prof Rod Baber

Menopausal Hormone Therapy - What Dose of Estrogen is Best?

Dr Adam Nelson

Dr Adam Nelson

Cardiovascular Benefits of GLP1s – New Evidence

Dr Kathleen McNamee, Prof Sonia Grover

Dr Kathleen McNamee, Prof Sonia Grover

Oral Contraceptive Pill in Teens

Prof Andrew Sindone

Prof Andrew Sindone

RSV and the Heart

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Michelle Ananda-Rajah

expert

Dr Michelle Ananda-Rajah

Infectious Diseases and General Medicine Physician; Founder, fungalAi; Co-Founder, Healthcare Workers Australia

Recent articles

Find your area of interest

Share this

You have completed the Educational Activities (EA) component of this activity.

Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.

You will be taken to explore further CPD learning available to you.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease